CO2017001875A2 - Terapia de combinación contra el alzheimer usando anticuerpos anti-n3pglu más un inhibidor bace - Google Patents
Terapia de combinación contra el alzheimer usando anticuerpos anti-n3pglu más un inhibidor baceInfo
- Publication number
- CO2017001875A2 CO2017001875A2 CONC2017/0001875A CO2017001875A CO2017001875A2 CO 2017001875 A2 CO2017001875 A2 CO 2017001875A2 CO 2017001875 A CO2017001875 A CO 2017001875A CO 2017001875 A2 CO2017001875 A2 CO 2017001875A2
- Authority
- CO
- Colombia
- Prior art keywords
- alzheimer
- combination therapy
- bace inhibitor
- antibodies plus
- n3pglu antibodies
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Endocrinology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Enzymes And Modification Thereof (AREA)
- Massaging Devices (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención proporciona un método para tratar una enfermedad neurodegenerativa o cognitiva, que comprende administrar a un paciente que necesite dicho tratamiento una cantidad eficaz de un compuesto de la fórmula: una sal farmacéuticamente aceptable de este; en combinación con una cantidad eficaz de un anticuerpo monoclonal Abeta anti-N3pGlu.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462050967P | 2014-09-16 | 2014-09-16 | |
| PCT/US2015/048807 WO2016043997A1 (en) | 2014-09-16 | 2015-09-08 | Combination alzheimer therapy using anti-n3pglu abeta antibodies + a bace inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2017001875A2 true CO2017001875A2 (es) | 2017-05-19 |
Family
ID=54207720
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2017/0001875A CO2017001875A2 (es) | 2014-09-16 | 2017-02-24 | Terapia de combinación contra el alzheimer usando anticuerpos anti-n3pglu más un inhibidor bace |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US9999624B2 (es) |
| EP (1) | EP3193882A1 (es) |
| JP (1) | JP6339741B2 (es) |
| KR (1) | KR101871128B1 (es) |
| CN (1) | CN106687136A (es) |
| AP (1) | AP2017009794A0 (es) |
| AR (1) | AR101740A1 (es) |
| AU (1) | AU2015318257B2 (es) |
| BR (1) | BR112017003571A2 (es) |
| CA (1) | CA2956835A1 (es) |
| CL (1) | CL2017000558A1 (es) |
| CO (1) | CO2017001875A2 (es) |
| CR (1) | CR20170080A (es) |
| DO (1) | DOP2017000071A (es) |
| EA (1) | EA031764B1 (es) |
| EC (1) | ECSP17015977A (es) |
| IL (1) | IL250387A0 (es) |
| MX (1) | MX2017003414A (es) |
| NZ (1) | NZ728636A (es) |
| PE (1) | PE20170464A1 (es) |
| PH (1) | PH12017500493A1 (es) |
| SG (1) | SG11201701330PA (es) |
| SV (1) | SV2017005389A (es) |
| TN (1) | TN2017000072A1 (es) |
| TW (1) | TWI599358B (es) |
| WO (1) | WO2016043997A1 (es) |
| ZA (1) | ZA201700826B (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20180119670A (ko) * | 2016-03-15 | 2018-11-02 | 아스트라제네카 아베 | 아밀로이드 베타의 축적과 관련된 질환의 치료를 위한 bace 억제제와 항체 또는 항원 결합 단편의 조합 |
| TWI798751B (zh) * | 2016-07-01 | 2023-04-11 | 美商美國禮來大藥廠 | 抗－N3pGlu類澱粉β肽抗體及其用途 |
| US10034861B2 (en) | 2016-07-04 | 2018-07-31 | H. Lundbeck A/S | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors |
| WO2018034977A1 (en) | 2016-08-18 | 2018-02-22 | Eli Lilly And Company | Combination therapy of bace-1 inhibitor and anti-n3pglu abeta antibody |
| AR110470A1 (es) * | 2016-10-21 | 2019-04-03 | Lilly Co Eli | Terapia de combinación para tratar la enfermedad de alzheimer |
| JP2020500841A (ja) | 2016-10-28 | 2020-01-16 | ハー・ルンドベック・アクチエゼルスカベット | イミダゾピラジノンの投与を含む併用療法 |
| JOP20190247A1 (ar) * | 2017-04-20 | 2019-10-20 | Lilly Co Eli | أجسام بيتا ببتيد النشوانية المضادة لـ N3pGlu واستخداماتها |
| US11634416B2 (en) | 2017-12-14 | 2023-04-25 | H. Lundbeck A/S | Combination treatments comprising administration of 1H-pyrazolo[4,3-b]pyridines |
| AR113926A1 (es) | 2017-12-14 | 2020-07-01 | H Lundbeck As | Derivados de 1h-pirazolo[4,3-b]piridinas |
| CN117447475A (zh) | 2017-12-20 | 2024-01-26 | H.隆德贝克有限公司 | 作为PDE1抑制剂的吡唑并[4,3-b]吡啶和咪唑并[1,5-a]嘧啶 |
| US10350226B1 (en) | 2018-06-27 | 2019-07-16 | Joshua O. Atiba | Therapy and prevention of prion protein complex infections |
| US20230236199A1 (en) * | 2020-04-23 | 2023-07-27 | Eli Lilly And Company | Subcutaneous absorption and bioavailability of antibodies |
| WO2024026472A2 (en) | 2022-07-29 | 2024-02-01 | Alector Llc | Transferrin receptor antigen-binding domains and uses therefor |
| WO2024026471A1 (en) | 2022-07-29 | 2024-02-01 | Alector Llc | Cd98hc antigen-binding domains and uses therefor |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005016876A2 (en) | 2003-08-08 | 2005-02-24 | Schering Corporation | Cyclic amine bace-1 inhibitors having a benzamide substituent |
| ES2548774T3 (es) | 2008-01-18 | 2015-10-20 | Eisai R&D Management Co., Ltd. | Derivado de aminodihidrotiazina condensado |
| CN103068848B (zh) * | 2010-08-12 | 2015-11-25 | 伊莱利利公司 | 抗N3pGlu淀粉样蛋白BETA肽抗体及其用途 |
| GB201101140D0 (en) | 2011-01-21 | 2011-03-09 | Eisai Ltd | Fused aminodihydrothiazine derivatives |
| TWI593692B (zh) | 2013-03-12 | 2017-08-01 | 美國禮來大藥廠 | 四氫吡咯并噻嗪化合物 |
-
2015
- 2015-09-01 TW TW104128851A patent/TWI599358B/zh not_active IP Right Cessation
- 2015-09-02 AR ARP150102803A patent/AR101740A1/es unknown
- 2015-09-08 MX MX2017003414A patent/MX2017003414A/es unknown
- 2015-09-08 PE PE2017000406A patent/PE20170464A1/es unknown
- 2015-09-08 BR BR112017003571A patent/BR112017003571A2/pt not_active Application Discontinuation
- 2015-09-08 NZ NZ728636A patent/NZ728636A/en not_active IP Right Cessation
- 2015-09-08 EA EA201790305A patent/EA031764B1/ru not_active IP Right Cessation
- 2015-09-08 AU AU2015318257A patent/AU2015318257B2/en not_active Ceased
- 2015-09-08 SG SG11201701330PA patent/SG11201701330PA/en unknown
- 2015-09-08 WO PCT/US2015/048807 patent/WO2016043997A1/en active Application Filing
- 2015-09-08 KR KR1020177006748A patent/KR101871128B1/ko active IP Right Grant
- 2015-09-08 EP EP15771800.8A patent/EP3193882A1/en not_active Withdrawn
- 2015-09-08 AP AP2017009794A patent/AP2017009794A0/en unknown
- 2015-09-08 US US15/503,027 patent/US9999624B2/en not_active Expired - Fee Related
- 2015-09-08 JP JP2017514623A patent/JP6339741B2/ja not_active Expired - Fee Related
- 2015-09-08 CR CR20170080A patent/CR20170080A/es unknown
- 2015-09-08 CN CN201580049574.0A patent/CN106687136A/zh active Pending
- 2015-09-08 TN TN2017000072A patent/TN2017000072A1/en unknown
- 2015-09-08 CA CA2956835A patent/CA2956835A1/en not_active Abandoned
-
2017
- 2017-02-01 IL IL250387A patent/IL250387A0/en unknown
- 2017-02-02 ZA ZA2017/00826A patent/ZA201700826B/en unknown
- 2017-02-22 SV SV2017005389A patent/SV2017005389A/es unknown
- 2017-02-24 CO CONC2017/0001875A patent/CO2017001875A2/es unknown
- 2017-03-08 CL CL2017000558A patent/CL2017000558A1/es unknown
- 2017-03-14 DO DO2017000071A patent/DOP2017000071A/es unknown
- 2017-03-15 PH PH12017500493A patent/PH12017500493A1/en unknown
- 2017-03-15 EC ECIEPI201715977A patent/ECSP17015977A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL250387A0 (en) | 2017-03-30 |
| EP3193882A1 (en) | 2017-07-26 |
| NZ728636A (en) | 2018-05-25 |
| TWI599358B (zh) | 2017-09-21 |
| KR101871128B1 (ko) | 2018-06-25 |
| US20170224702A1 (en) | 2017-08-10 |
| ZA201700826B (en) | 2018-12-19 |
| KR20170036103A (ko) | 2017-03-31 |
| PH12017500493A1 (en) | 2017-08-07 |
| AU2015318257B2 (en) | 2018-06-14 |
| CN106687136A (zh) | 2017-05-17 |
| SV2017005389A (es) | 2018-01-17 |
| JP6339741B2 (ja) | 2018-06-06 |
| PE20170464A1 (es) | 2017-04-26 |
| ECSP17015977A (es) | 2018-03-31 |
| US9999624B2 (en) | 2018-06-19 |
| CR20170080A (es) | 2017-03-30 |
| WO2016043997A1 (en) | 2016-03-24 |
| EA201790305A1 (ru) | 2017-07-31 |
| CL2017000558A1 (es) | 2017-11-10 |
| TN2017000072A1 (en) | 2018-07-04 |
| TW201618786A (zh) | 2016-06-01 |
| AU2015318257A1 (en) | 2017-02-16 |
| BR112017003571A2 (pt) | 2017-12-19 |
| AP2017009794A0 (en) | 2017-03-31 |
| EA031764B1 (ru) | 2019-02-28 |
| SG11201701330PA (en) | 2017-04-27 |
| JP2017529348A (ja) | 2017-10-05 |
| MX2017003414A (es) | 2017-06-19 |
| AR101740A1 (es) | 2017-01-11 |
| CA2956835A1 (en) | 2016-03-24 |
| DOP2017000071A (es) | 2017-06-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2017001875A2 (es) | Terapia de combinación contra el alzheimer usando anticuerpos anti-n3pglu más un inhibidor bace | |
| DOP2019000187A (es) | Compuestos de 5-metil-1,2,4-oxadiazol-3-ilo | |
| PH12018500041A1 (en) | Substituted aza compoounds as irak-4 inhibitors | |
| PE20170673A1 (es) | Terapia de combinacion para tratar una paramixovirus | |
| PH12016502382A1 (en) | Substituted indazole compounds as irak4 inhibitors | |
| EA201791017A1 (ru) | Гидроксисодержащие соединения, модулирующие fxr (nr1h4) | |
| EA201791420A1 (ru) | Соединения триазолопиримидина и их применения | |
| NZ712207A (en) | Tetrahydropyrrolothiazine compounds | |
| EA201391485A1 (ru) | Способы и композиции для лечения нейродегенеративных заболеваний | |
| CR20140052A (es) | Un derivado novedoso de 1,2,3,4-tetrahidroquinolina útil para el tratamiento de diabetes | |
| MX2021006901A (es) | Agentes terapeuticos para enfermedades neurodegenerativas. | |
| EA201692481A1 (ru) | Комбинация, содержащая глюкокортикоид и edo-s101 | |
| EA201791227A1 (ru) | РЕЖИМ ДОЗИРОВАНИЯ АНТАГОНИСТОВ MAdCAM | |
| BR112015011798A2 (pt) | métodos e composições para tratar doenças neurodegenerativas | |
| MX2016008968A (es) | Compuestos organicos. | |
| BR112018002763A2 (pt) | método para cicatrização de ferimentos | |
| EA201990559A1 (ru) | Комбинированная терапия | |
| NZ728612A (en) | Treatment of androgen deprivation therapy associated symptoms | |
| MX2017002093A (es) | Terapia con anticuerpos para vih como sustituto de tratamiento. | |
| AR099416A1 (es) | Terapia combinada para la hipertensión resistente | |
| WO2016069477A3 (en) | A method of treating cancer that overexpresses topbp1 | |
| AR109209A1 (es) | Composición farmacéutica para prevención o tratamiento de enfermedades neurodegenerativas | |
| EA201301340A1 (ru) | Фармацевтическая композиция, обладающая нейропротекторным действием, её применение и способы повышения жизнеспособности и профилактики или лечения цереброваскулярных и нейродегенеративных заболеваний | |
| EA202090453A2 (ru) | Антитела к cd40 |